Company / R&D Expense
Theravance Biopharma, Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$37.4M
FY2025
5-year range
$37.4M / $261.0M
FY2021-FY2025
Trend
-0.6%
vs FY2024
Sector context
#187 of 210
Health Care
What the data says
Theravance Biopharma, Inc.'s r&d expense of $37M is lower than 89% of companies in the Health Care sector (FY2025). R&D Expense has declined for 3 consecutive years, from $261M in FY2022 to $37M in FY2025.
Based on SEC 10-K filings.
$37M in FY2025 with a 5-year CAGR of -32.2%.
Declined from $41M to $37M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -47.7%
- 5-Year CAGR
- -32.2%
- 10-Year CAGR
- -
Sector benchmark
Bottom 11% in Health CareTop 89% of 210This company $37.4M Sector average $644.1M
▼
-94.2% below sector average
Key checks
Key Insights
- Theravance Biopharma, Inc.'s r&d expense has declined for 3 consecutive years.
- 5-year CAGR of -32.2%, indicating a declining trend.
- In FY2025, r&d expense decreased 0.6% year-over-year.
- Ranks #187 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $37.4M | -0.6% |
| FY2024 | $37.6M | -7.3% |
| FY2023 | $40.6M | -84.4% |
| FY2022 | $261.0M | +34.8% |
| FY2021 | $193.7M | -25.8% |
| FY2020 | $261.0M | +50.1% |
| FY2019 | $173.9M | +22.7% |
| FY2018 | $141.7M | -18.5% |
| FY2017 | $173.9M | +22.7% |
| FY2016 | $141.7M | +17.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026